Sun Pharmaceutical Industries Ltd.


  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Feb 22, 2018
Prev close: 542.15
Feb 22, 2018
Market cap:
Market cap(USD):
Shares: 2,399.24M

Currency in INR

Company profile

Market(Ticker): BOM(524715)
Health Technology
Pharmaceuticals: Major
Full time employees: 30,000

Business summary

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It operates through the following geographical segments: India, the United States of America, Emerging Markets, and Rest of the World. It offers tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1982 and is headquartered in Mumbai, India.

Company background

Sun Pharmaceutical is India's largest drugmaker. It sells mainly generic drugs, an area in which Indian companies do well, in more than 150 countries, including the U.S. It has over 20 production bases around the world and supplies more than 1,000 products. It has succeeded in expanding its business globally, given that domestic sales account for only about 30% of its group sales. It has built a solid business base especially in the U.S., generating more around 50% of sales in that market.

The company was founded in 1983 by Dilip Shanghvi, who serves as managing director. It brought online its first active pharmaceutical ingredients factory in the western Indian state of Gujarat in 1995. It has been on a growth path recently on the back of the global expansion of India's generic drug business. Shanghvi is known for his aggressive merger and acquisition strategy and has expanded his company through buyouts including overseas companies. In 2014, it bought Ranbaxy Laboratories, an Indian drugmaker, which cemented its place at the top of India's pharmaceutical industry.

Shanghvi and other founding family members and affiliate companies own more than 60% of shares in Sun Pharmaceutical. Shanghvi is one of India's richest men, and he and his family are actively investing in India.

In the news

Financial highlights

Mar 2017

  • Local currency
  • US Dollar
Revenue 313,081.4M
Gross profit 158,651.2M
Operating income 84,884.5M
Income before tax 90,478.7M
Net income 69,643.7M
EBITDA 97,532M
Diluted EPS 29
Dividends per share 3.5
Total assets 619,117.9M
Total liabilities 214,674.7M
Total equity 366,396.7M
Operating cash flow 71,269.5M

Currency in INR

Revenue 4,668.88M
Gross profit 2,365.91M
Operating income 1,265.85M
Income before tax 1,349.27M
Net income 1,038.57M
EBITDA 1,454.46M
Diluted EPS 0.43
Dividends per share 0.05
Total assets 9,534.42M
Total liabilities 3,305.99M
Total equity 5,642.51M
Operating cash flow 1,062.81M

Currency in USD

Valuation measures

Mar 2017

PER 23.71
ROA 11.81%
ROE 20.00%
Operating margin 27.11%
Profit margin 22.24%

Key executive

  • Managing Director & Executive Director: Dilip Shantilal Shanghvi
  • Chief Financial Officer: C. S. Muralidharan
  • Compliance Officer, General Manager-Secretarial: Ashok I. Bhuta
  • Vice President & Global Head-Regulatory: Rajeev S. Mathur
  • Senior Vice President-Business Development: Kirti Wardhaman Ganorkar

Share holders

  • Viditi Investments Pvt Ltd.(8.3%)
  • Tejaskiran Pharmachem Industries Pvt Ltd.(8.1%)
  • Family Investment Pvt Ltd.(7.6%)
  • Quality Synthetic Industries Ltd.(7.6%)
  • Life Insurance Corp. of India(5.5%)
  • Virtuous Finance Ltd.(4.0%)
  • Virtuous Share Investments Pvt Ltd.(3.4%)
  • ICICI Prudential Asset Management Co. Ltd.(2.6%)
  • Aditya Medisales Ltd.(1.6%)


  • Website:
  • Address: CTS No. 201 B/1, Sun House, Western Express Highway, Mumbai, 400063, India
  • Phone: +91.22.43244324

Copyright © 2018 FactSet Research Systems Inc. All rights reserved.